These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17476281)

  • 41. Leukemia incidence following primary breast carcinoma treatment.
    Kaplan HG; Malmgren JA; Atwood M
    Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methylenetetrahydrofolate reductase and glutathione S-tranferase gene polymorphisms in secondary mixed phenotype acute leukemia: a case report.
    Skoric D; Ivana J; Tanja R; Jovana J; Petar I; Tatjana S
    J Pediatr Hematol Oncol; 2014 Apr; 36(3):e152-4. PubMed ID: 24276031
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients.
    Chaturvedi P; Tulsyan S; Agarwal G; Lal P; Agrawal S; Mittal RD; Mittal B
    Biochem Genet; 2015 Aug; 53(7-8):211-22. PubMed ID: 26014925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapy-related leukemia and myelodysplasia: susceptibility and incidence.
    Leone G; Pagano L; Ben-Yehuda D; Voso MT
    Haematologica; 2007 Oct; 92(10):1389-98. PubMed ID: 17768113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of MTHFR polymorphisms and chromosomal abnormalities in leukemia.
    Sinthuwiwat T; Poowasanpetch P; Wongngamrungroj A; Soonklang K; Promso S; Auewarakul C; Tocharoentanaphol C
    Dis Markers; 2012; 32(2):115-21. PubMed ID: 22377705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secondary hematological malignancies after breast cancer chemotherapy.
    Park MJ; Park YH; Ahn HJ; Choi W; Paik KH; Kim JM; Chang YH; Ryoo BY; Yang SH
    Leuk Lymphoma; 2005 Aug; 46(8):1183-8. PubMed ID: 16085560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment.
    Zárate R; González-Santigo S; de la Haba J; Bandres E; Morales R; Salgado J; Gómez A; Aranda E; García-Foncillas J
    Curr Drug Metab; 2007 Jun; 8(5):481-6. PubMed ID: 17584018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapy-related acute myeloid leukemia: role of DNA repair].
    Guièze R; Ravinet A; Hermet E; Maliki Y; de Botton S; Bay JO
    Bull Cancer; 2011 Mar; 98(3):247-55. PubMed ID: 21427028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers.
    Beadle G; Baade P; Fritschi L
    Ann Oncol; 2009 Jan; 20(1):103-9. PubMed ID: 18647961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Leukaemogenesis, gene interplay, and the role of the haemopoietic environment.
    Lawler M
    Radiat Oncol Investig; 1997; 5(3):154-7. PubMed ID: 9303075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increase therapy-related leukemia secondary to breast cancer.
    Carli PM; Sgro C; Parchin-Geneste N; Isambert N; Mugneret F; Girodon F; Maynadié M
    Leukemia; 2000 Jun; 14(6):1014-7. PubMed ID: 10865966
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment-related MDS/AML in a patient after treatment for large-cell neuroendocrine lung cancer.
    Ansari J; Ravipati HP; Munker R; Cotelingam JD; Shackelford RE; Prouty LA
    J Community Support Oncol; 2015 Nov; 13(11):411-4. PubMed ID: 26863022
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Genetics of hereditary hematological malignancies].
    Takagi M
    Rinsho Ketsueki; 2015 Oct; 56(10):1969-77. PubMed ID: 26458435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.
    Moreno Berggren D; Garelius H; Willner Hjelm P; Nilsson L; Rasmussen B; Weibull CE; Lambe M; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
    Leukemia; 2023 May; 37(5):1103-1112. PubMed ID: 36928008
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Carcinogenic potential of antitumor therapies - is the risk predictable?
    Nenova I; Grudeva-Popova J
    J BUON; 2017; 22(6):1378-1384. PubMed ID: 29332326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA repair and the risk of secondary leukemias.
    Gerson SL
    J Clin Oncol; 1996 Feb; 14(2):681-2. PubMed ID: 8636789
    [No Abstract]   [Full Text] [Related]  

  • 57. Genetic susceptibility to iatrogenic malignancy.
    Allan JM; Rabkin CS
    Pharmacogenomics; 2005 Sep; 6(6):615-28. PubMed ID: 16143001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Karyotyping of a hematologic neoplasia developing shortly after treatment for cerebral extragonadal germ cell tumor.
    Heimdal K; Evensen SA; Fosså SD; Hirscberg H; Langholm R; Brøgger A; Møller P
    Cancer Genet Cytogenet; 1991 Nov; 57(1):41-6. PubMed ID: 1756483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germline polymorphisms and the risk of therapy-related myeloid neoplasms.
    Takahashi K
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):24-30. PubMed ID: 30927971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic Malignancies.
    Comen EA; Bowman RL; Selenica P; Kleppe M; Farnoud NR; Pareja F; Weigelt B; Hill CE; Alon A; Geyer FC; Akturk G; Reis-Filho JS; Norton L; Levine RL
    J Natl Cancer Inst; 2020 Jan; 112(1):107-110. PubMed ID: 31504684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.